ライフサイエンスコーパス: left ventricular hypertrophy

1 ubjects (sarcomere mutation carriers without left ventricular hypertrophy).

2 cretion, has been inconsistently linked with left ventricular hypertrophy.

3 ed with HCTZ, CTDN was associated with lower left ventricular hypertrophy.

4 entiating CA from other causes of concentric left ventricular hypertrophy.

5 ressive aortic valve narrowing and secondary left ventricular hypertrophy.

6 of 18 children with normal echoes developed left ventricular hypertrophy.

7 risk of sudden cardiac death (SCD) and mild left ventricular hypertrophy.

8 risk factors, particularly hypertension and left ventricular hypertrophy.

9 tical aortic stenosis often have significant left ventricular hypertrophy.

10 tolic blood pressures, cardiac fibrosis, and left ventricular hypertrophy.

11 e a hallmark of mitochondrial dysfunction in left ventricular hypertrophy.

12 but in none of the mutation carriers without left ventricular hypertrophy.

13 baseline risk factors plus electrocardiogram left ventricular hypertrophy.

14 tihypertensive therapy and regression of ECG left ventricular hypertrophy.

15 Hg are associated in a 7-yr study to reverse left ventricular hypertrophy.

16 ystem and can predispose to hypertension and left ventricular hypertrophy.

17 tolic blood pressure, diabetes, smoking, and left ventricular hypertrophy.

18 ling cascades involved in the development of left ventricular hypertrophy.

19 a novel and useful therapeutic strategy for left ventricular hypertrophy.

20 gs survival in a model of severe progressive left ventricular hypertrophy.

21 e cell-matrix interactions in the context of left ventricular hypertrophy.

22 eta blockers as first-line agents to regress left ventricular hypertrophy.

23 sarcomere mutation carriers with and without left ventricular hypertrophy.

24 ould not be guided solely on the severity of left ventricular hypertrophy.

25 iated with incident hypertension and risk of left ventricular hypertrophy.

26 tify individuals at risk for hypertension or left ventricular hypertrophy.

27 a sickle cell positive athlete who also had left ventricular hypertrophy.

28 nd a mixed logistic model was used to assess left ventricular hypertrophy.

29 and regional wall motion abnormalities, and left-ventricular hypertrophy.

30 ects (6%), mitral valve abnormalities (51%), left ventricular hypertrophy (19%), and atrial fibrillat

31 ant increase in the prevalence of concentric left ventricular hypertrophy (2 of 64 [3%] versus 20 of

32 e heart failure (43% versus 34%; P=0.04) and left ventricular hypertrophy (77% versus 58%; P=0.02) an

33 conventional paradigm of the progression of left ventricular hypertrophy, a thick-walled left ventri

34 Left ventricular hypertrophy (adjusted hazard ratio, 1.5

35 The decrease in the prevalence of left ventricular hypertrophy after renal transplantation

36 ts with hypertrophic cardiomyopathy (HCM) or left ventricular hypertrophy also present with skeletal

37 nd was significantly associated with greater left ventricular hypertrophy and a higher prevalence of

38 p65 NF-kappaB deletion promoted maladaptive left ventricular hypertrophy and accelerated progression

39 diovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that

40 Extreme left ventricular hypertrophy and blunted blood pressure

41 the heart against pressure overload-induced left ventricular hypertrophy and CHF.

42 unted, and the hearts were protected against left ventricular hypertrophy and CHF.

43 Left ventricular hypertrophy and coronary artery calcifi

44 ed FGF-23 concentrations are associated with left ventricular hypertrophy and coronary artery calcifi

45 promote atrial fibrillation (AF) by inducing left ventricular hypertrophy and diastolic and left atri

46 HFHS diet-fed mice developed progressive left ventricular hypertrophy and diastolic dysfunction w

47 eatment with S17834 or resveratrol prevented left ventricular hypertrophy and diastolic dysfunction.

48 ith metabolic heart disease characterized by left ventricular hypertrophy and diastolic dysfunction.

49 preserved FEV1/FVC ratio is associated with left ventricular hypertrophy and diastolic dysfunction.

50 -tg and Kir6.2 KO mice developed more severe left ventricular hypertrophy and dysfunction as compared

51 Early markers of cardiomyopathy, such as left ventricular hypertrophy and dysfunction, and early

52 approach to treat pressure overload-induced left ventricular hypertrophy and dysfunction.

53 Indices of left ventricular hypertrophy and ejection fraction were

54 regression of target end organ effects like left ventricular hypertrophy and endothelial dysfunction

55 reclinical cardiovascular disease, including left ventricular hypertrophy and evidence of increased a

56 angiotensin II receptor blocker losartan on left ventricular hypertrophy and fibrosis in patients wi

57 the renin-angiotensin system contributes to left ventricular hypertrophy and fibrosis, a major deter

58 Grx2(-/-) hearts also developed left ventricular hypertrophy and fibrosis, and mice beca

59 Left ventricular hypertrophy and fibrosis, collagen depo

60 fects of angiotensin II receptor blockers on left ventricular hypertrophy and fibrosis, which are pre

61 ulating miRNAs correlated with the degree of left ventricular hypertrophy and fibrosis.

62 ce developed cardiomyopathy characterized by left ventricular hypertrophy and glycogen accumulation,

63 ficantly higher in mutation carriers without left ventricular hypertrophy and in subjects with overt

64 Osteopontin (OPN) is upregulated in left ventricular hypertrophy and is stimulated by angiot

65 lence of structural heart disease, including left ventricular hypertrophy and left atrial enlargement

66 Echocardiographic data showed left ventricular hypertrophy and lower fractional shorte

67 lipid accumulation in the myocardium causes left ventricular hypertrophy and nonischemic, dilated ca

68 imal-medial thickness, and echocardiographic left ventricular hypertrophy and systolic dysfunction.

69 omyopathy, 39 subjects with mutations but no left ventricular hypertrophy, and 30 controls who did no

70 ltimorbidity, impaired chronotropic reserve, left ventricular hypertrophy, and activation of inflamma

71 tricular systolic and diastolic dysfunction, left ventricular hypertrophy, and alterations in the cor

72 n increased relative wall thickness or overt left ventricular hypertrophy, and associated diastolic d

73 HFpEF mice developed hypertension, left ventricular hypertrophy, and diastolic dysfunction

74 type mice developed HFpEF with hypertension, left ventricular hypertrophy, and diastolic dysfunction.

75 onary heart disease, valvular heart disease, left ventricular hypertrophy, and estimated glomerular f

76 rats showed higher body weight, significant left ventricular hypertrophy, and impaired diastolic fun

77 maladaptive concentrations, and then induces left ventricular hypertrophy, and is possibly implicated

78 djusted for risk factors including diabetes, left ventricular hypertrophy, and ischemia (adjusted haz

79 Patients with increased age, left ventricular hypertrophy, and left atrial dilatation

80 rate, hypertension, cardiovascular disease, left ventricular hypertrophy, and left bundle-branch blo

81 cardial infarction, lower ejection fraction, left ventricular hypertrophy, and left ventricular dilat

82 versing cardiovascular complications such as left ventricular hypertrophy, and minimizing the use of

83 s are linked to CKD and greater risk of CVD, left ventricular hypertrophy, and mortality in dialysis

84 ith chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventric

85 ltage criteria for right ventricular (RV) or left ventricular hypertrophy, and symmetrical cardiac en

86 h stage B HF (normal exercise tolerance with left ventricular hypertrophy, and/or reduced global long

87 : vascular dysfunction; arterial stiffening; left ventricular hypertrophy; and worsened metrics of di

88 n velocity (CV) and conduction anisotropy in left ventricular hypertrophy are associated with topogra

89 s following myocardial infarction and during left ventricular hypertrophy as surrogate markers of rem

90 ossible mechanistic role of exercise-induced left ventricular hypertrophy as the basis for J-point el

91 pertrophy, and also 2 survivors with extreme left ventricular hypertrophy at age 15 years.

92 lysis on LVM was evident among patients with left ventricular hypertrophy at baseline.

93 diastolic dysfunction pathway that includes left ventricular hypertrophy, atrial enlargement, and he

94 c blood pressure, current smoking, diabetes, left ventricular hypertrophy, atrial fibrillation, and p

95 changes, ventricular conduction defects, and left ventricular hypertrophy based on the Minnesota code

96 GR-1 exhibited a significant attenuation of left ventricular hypertrophy based on tissue weight asse

97 ing ECG (ST-segment or T-wave abnormalities, left ventricular hypertrophy, bundle branch block, or le

98 trongly associated with HFpEF, and male sex, left ventricular hypertrophy, bundle branch block, previ

99 High FGF-23 levels promote left ventricular hypertrophy but not coronary artery cal

100 It is characterised by left ventricular hypertrophy but there is an important p

101 a(2+)ATPase and phospholamban were normal in left ventricular hypertrophy, but decreased in failing h

102 atments have shown improvement in regressing left ventricular hypertrophy, but inhibitors of the reni

103 hypertension is linked to the development of left ventricular hypertrophy, but whether this associati

104 e known predictive value of in-treatment ECG left ventricular hypertrophy by Cornell product and Soko

105 a novel multimodality testing strategy using left ventricular hypertrophy by ECG, coronary artery cal

106 e free from CVD and underwent measurement of left ventricular hypertrophy by ECG, coronary artery cal

107 T was also strongly associated with incident left ventricular hypertrophy by electrocardiography over

108 carotid intima-media thickness or stenosis, left ventricular hypertrophy [by ECG or echocardiography

109 od pressure, cholesterol, diabetes, smoking, left ventricular hypertrophy, C-reactive protein, age, a

110 in selected areas, such as undifferentiated left ventricular hypertrophy, cardio-oncology, aortic st

111 ndividuals: sarcomere mutation carriers with left ventricular hypertrophy (clinical HCM; n=36), mutat

112 Over 4 years, the adjusted prevalence of left ventricular hypertrophy decreased from 15.3% to 12.

113 rrelation between the level of hypertension, left ventricular hypertrophy, deterioration of GFR, and

114 Hypertension leads to left ventricular hypertrophy, diastolic dysfunction, and

115 adiponectin deficiency in HFpEF exacerbates left ventricular hypertrophy, diastolic dysfunction, and

116 sion in aldosterone-infused mice ameliorated left ventricular hypertrophy, diastolic dysfunction, lun

117 ic with structural abnormalities, defined as left ventricular hypertrophy, dilation or dysfunction, o

118 c background lacked hallmarks of HCM such as left ventricular hypertrophy, disarray of myofibers, and

119 sure overload-induced cardiac stress induces left ventricular hypertrophy driven by increased cardiom

120 ree major conditions (myocardial infarction, left ventricular hypertrophy due to overload, and dilate

121 olonged-QT commonly coexists in the ECG with left ventricular hypertrophy (ECG-LVH).

122 y is evident, illustrated by the presence of left ventricular hypertrophy, even in young children.

123 ceptor density in nonfailing, hypertrophied (left ventricular hypertrophy), failing, and failing left

124 lates age-related cardiac changes in humans (left ventricular hypertrophy, fibrosis and diastolic dys

125 CM), typically characterized by asymmetrical left ventricular hypertrophy, frequently is caused by mu

126 e in 64% and a decrease in the prevalence of left ventricular hypertrophy from 66% to 56%.

127 may be present in mutation carriers without left ventricular hypertrophy (G+LVH-) but are difficult

128 HRadjBMI and BMI were associated with higher left ventricular hypertrophy, glycemic traits, interleuk

129 evaluation; 38 were clinically affected with left ventricular hypertrophy >/=13 mm.

130 Left ventricular hypertrophy has been identified as an i

131 patients with genetic mutations but without left-ventricular hypertrophy has emerged, with unresolve

132 o traffic-related air pollution is linked to left ventricular hypertrophy, heart failure, and death.

133 y disease (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death.

134 paired glucose metabolism, renal impairment, left ventricular hypertrophy, heart failure, and others.

135 ection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular fi

136 from those in individuals with hypertensive left ventricular hypertrophy (HLVH) of similar age, gend

137 ystolic strain in hypertensive patients with left ventricular hypertrophy (HTN LVH) and hypertensive

138 Hypertensive left ventricular hypertrophy (HTN-LVH) is a leading caus

139 ular disease, diabetes, electrocardiographic left ventricular hypertrophy, hypertension treatment, an

140 diagnosis is based on otherwise unexplained left-ventricular hypertrophy identified by echocardiogra

141 duals) with predominant clinical features of left ventricular hypertrophy in addition to cardiac dila

142 ed the role of CLP-1 in vivo in induction of left ventricular hypertrophy in angiotensinogen-overexpr

143 of hypertension and hypertension-associated left ventricular hypertrophy in blacks, we hypothesized

144 hat a decline in BP may predict a decline in left ventricular hypertrophy in children with CKD and su

145 regulatory hormone that directly stimulates left ventricular hypertrophy in experimental models.

146 Left ventricular hypertrophy in hypertension develops ev

147 The pathogenesis of left ventricular hypertrophy in patients with CKD is inc

148 ociated with left ventricular mass index and left ventricular hypertrophy in patients with CKD.

149 ociated with hypertensive heart disease with left ventricular hypertrophy in the absence of coronary

150 nt additional investigation as predictors of left ventricular hypertrophy in these patients.

151 contractile dysfunction in pressure-overload left ventricular hypertrophy in vivo.

152 icacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine c

153 lood pressure (BP) is an important marker of left ventricular hypertrophy, incident hypertension, and

154 Predictors of left ventricular hypertrophy included systolic BP, femal

155 Prevalence of left ventricular hypertrophy increased from 7.5% (95% CI

156 The prevalence of hypertension and left ventricular hypertrophy increased with the degree o

157 db/db mice and is associated with aging and left ventricular hypertrophy, increased DNA damage, and

158 with a HFHS diet prevent the development of left ventricular hypertrophy, interstitial fibrosis, and

159 We hypothesized that athletic left ventricular hypertrophy is a consequence of increas

160 Left ventricular hypertrophy is absent in the minority o

161 Left ventricular hypertrophy is an initial compensatory

162 Left ventricular hypertrophy is rare in children with TN

163 t are especially prevalent in late life (eg, left ventricular hypertrophy, ischemic heart disease, he

164 arrowing and then examine the development of left ventricular hypertrophy, its subsequent decompensat

165 pEF, characterized by diastolic dysfunction, left ventricular hypertrophy, left atrial dilatation, an

166 n, sleep disordered breathing, inflammation, left ventricular hypertrophy, left atrial enlargement, a

167 Left ventricular hypertrophy, left atrial volume, AEVS,

168 pecific model additionally included smoking, left ventricular hypertrophy, left bundle branch block,

169 e common for defining cardiac traits such as left ventricular hypertrophy, left ventricular ejection

170 minal probrain natriuretic peptide level and left ventricular hypertrophy, left ventricular systolic

171 We tested 2 hypotheses: (1) chronic left ventricular hypertrophy (LVH) activates the proteas

172 Left ventricular hypertrophy (LVH) and anemia are highly

173 1 in the DT (FGFR1(DT-cKO) mice) resulted in left ventricular hypertrophy (LVH) and decreased kidney

174 Left ventricular hypertrophy (LVH) and diastolic dysfunc

175 neously hypertensive rat (SHR) as a model of left ventricular hypertrophy (LVH) and failure.

176 Left ventricular hypertrophy (LVH) and inflammation inde

177 this study was to examine the prevalence of left ventricular hypertrophy (LVH) and left ventricular

178 -based renal sympathetic denervation (RD) on left ventricular hypertrophy (LVH) and systolic and dias

179 ne the association of exercise capacity with left ventricular hypertrophy (LVH) and systolic/diastoli

180 tected in 40% of cases, including idiopathic left ventricular hypertrophy (LVH) and/or fibrosis (n =

181 resence and severity of electrocardiographic left ventricular hypertrophy (LVH) appear to predict dev

182 ences between physiological and pathological left ventricular hypertrophy (LVH) are of intense intere

183 These hypertensive rats had left ventricular hypertrophy (LVH) as well as increases

184 The prevalence of left ventricular hypertrophy (LVH) assessed by echocardi

185 Left ventricular hypertrophy (LVH) associates with incre

186 tress identify asymptomatic individuals with left ventricular hypertrophy (LVH) at higher risk for he

187 by mutations in sarcomere protein genes, and left ventricular hypertrophy (LVH) develops as an adapti

188 ns seem to induce profibrotic changes before left ventricular hypertrophy (LVH) develops.

189 Reduction of electrocardiographic left ventricular hypertrophy (LVH) has been associated w

190 ographic (ECG) criteria for the diagnosis of left ventricular hypertrophy (LVH) have low sensitivity.

191 Prevalence of concentric left ventricular hypertrophy (LVH) improved from 28% at

192 ic impact of ECG left ventricular strain and left ventricular hypertrophy (LVH) in asymptomatic aorti

193 d would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients with hype

194 ibitors proved to be effective in regressing left ventricular hypertrophy (LVH) in renal transplant r

195 rophic myocyte growth and the development of left ventricular hypertrophy (LVH) in rodents.

196 T-wave inversion is strongly associated with left ventricular hypertrophy (LVH) independently of coro

197 ates in pig cardiac tissue, with and without left ventricular hypertrophy (LVH) induced by aortic ban

198 Left ventricular hypertrophy (LVH) is an important mecha

199 Left ventricular hypertrophy (LVH) is associated with el

200 Left ventricular hypertrophy (LVH) is common in T2DM and

201 Left ventricular hypertrophy (LVH) is usually accompanie

202 BP including coronary artery disease (CAD), left ventricular hypertrophy (LVH) or stroke.

203 The progression of pressure-overload left ventricular hypertrophy (LVH) to chronic heart fail

204 Left ventricular hypertrophy (LVH) typically manifests d

205 cardiac AL amyloidosis, asymmetrical septal left ventricular hypertrophy (LVH) was present in 79% of

206 Left ventricular hypertrophy (LVH) with and without hear

207 8 weeks after ascending aortic constriction (left ventricular hypertrophy (LVH)) or sham operation.

208 dy sought to examine the association between left ventricular hypertrophy (LVH), de fi ned by cardiac

209 te marker of congestive heart failure (CHF), left ventricular hypertrophy (LVH), diabetes mellitus (D

210 ts with chronic kidney disease (CKD) reduces left ventricular hypertrophy (LVH), which is a risk fact

211 RAF1 alleles typically develop pathological left ventricular hypertrophy (LVH), which is reproduced

212 structural changes before the development of left ventricular hypertrophy (LVH).

213 intracellular lipid disorder that can cause left ventricular hypertrophy (LVH).

214 re impaired in HCM mutation carriers without left ventricular hypertrophy (LVH).

215 associated with worse allograft function and left ventricular hypertrophy (LVH).

216 nt in arterial compliance might also regress left ventricular hypertrophy (LVH).

217 ses (ERK) pathway plays an important role in left ventricular hypertrophy (LVH).

218 on has been implicated in the development of left ventricular hypertrophy (LVH).

219 rmal subjects and to evaluate the effects of left ventricular hypertrophy (LVH).

220 in signaling pathway within the heart causes left ventricular hypertrophy (LVH).

221 ntial adaptive cardiac modifications such as left ventricular hypertrophy (LVH).

222 55 healthy athletes with mild physiological left ventricular hypertrophy (LVH).

223 in CKD, it may contribute mechanistically to left ventricular hypertrophy (LVH).

224 morbidity and mortality and with greater ECG left ventricular hypertrophy (LVH); however, it is uncle

225 Left ventricular hypertrophy (LVH; high LV mass [LVM]) i

226 25 patients with essential hypertension and left ventricular hypertrophy (LVH[+]) and 24 normal cont

227 ts, accelerated coronary atherosclerosis and left ventricular hypertrophy manifest in the fourth deca

228 Persistence of the left ventricular hypertrophy may result from the combine

229 Arterial stiffness and left ventricular hypertrophy may significantly influence

230 resistance, thus leading to hypertension and left ventricular hypertrophy, metabolic syndrome/diabete

231 Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cogn

232 We analyzed data from a canine left ventricular hypertrophy model to determine how the

233 thesize that altered metabolic properties in left ventricular hypertrophy modulate DeltaPsi(m) spatio

234 c constriction (TAC), ST2(-/-) mice had more left ventricular hypertrophy, more chamber dilation, red

235 variety of cardiac disease processes such as left ventricular hypertrophy, myocardial ischemia, and d

236 autosomal dominant disease characterized by left ventricular hypertrophy, myofibrillar disarray and

237 Compared with those without left ventricular hypertrophy (n=51) and left ventricular

238 uded family history of sudden death, massive left ventricular hypertrophy, nonsustained ventricular t

239 ge, gender, hypertension, diabetes mellitus, left ventricular hypertrophy, obesity, serum total chole

240 l of transverse aortic constriction in which left ventricular hypertrophy occurred by 2 weeks without

241 increase in log FGF-23; P=0.01) and risk of left ventricular hypertrophy (odds ratio per 1-SD increa

242 Unexplained left ventricular hypertrophy often prompts the diagnosis

243 Left ventricular hypertrophy on ECG was a strong predict

244 event, it was independently associated with left ventricular hypertrophy only in women.

245 Left ventricular hypertrophy or concentric remodeling, L

246 seline muscle contraction was not altered in left ventricular hypertrophy or failing hearts.

247 rofibrotic state preceded the development of left ventricular hypertrophy or fibrosis visible on MRI.

248 f chronic heart failure secondary to chronic left ventricular hypertrophy or myocardial infarction.

249 data in the patients with diabetes mellitus, left ventricular hypertrophy, or myocardial infarction.

250 al fibrosis in the absence of myocarditis or left ventricular hypertrophy, or other known pathogenese

251 tability requiring a salvage CABG operation, left ventricular hypertrophy, or previous CABG.

252 (p < 0.01); NSVT was associated with greater left ventricular hypertrophy (p = 0.01) and severe sympt

253 tudy who were free of myocardial infarction, left ventricular hypertrophy, pacemaker, and with QRS <1

254 However, correlation with left ventricular hypertrophy parameters holds true for o

255 ncrease in log FGF-23; P=0.01; odds ratio of left ventricular hypertrophy per 1-SD increase in log FG

256 pe analyses we find association of NRG1 with left ventricular hypertrophy phenotypes, fibrinogen and

257 ACSM3, ERI2, IL18RAP, IL23RAP and NRG1) with left ventricular hypertrophy phenotypes.

258 natriuretic peptide, which is induced during left ventricular hypertrophy, plays an anti-fibrogenic a

259 ), aortic dissection (3, 8%), and idiopathic left ventricular hypertrophy/possible hypertrophic cardi

260 Aortic valve area and left ventricular hypertrophy predicted symptom developme

261 Rather than developing compensatory left ventricular hypertrophy, pressure overload in cardi

262 aving a higher proportion of males, smokers, left ventricular hypertrophy, previous left heart cathet

263 abnormalities included voltage criteria for left ventricular hypertrophy, prolongation of the correc

264 esis, A(3)R KO attenuated 5-week TAC-induced left ventricular hypertrophy (ratio of ventricular mass/

265 oidosis (CA) from other causes of concentric left ventricular hypertrophy remains a clinical challeng

266 s are decreased in pressure overload-induced left ventricular hypertrophy, resulting in action potent

267 >2.1 differentiated CA from other causes of left ventricular hypertrophy (sensitivity, 88%; specific

268 ic BP, hypertension, cardiovascular disease, left ventricular hypertrophy, smoking, alcohol use, educ

269 tability, shock, intravenous nitroglycerine, left-ventricular hypertrophy, sustained ventricular arrh

270 rbor silent cTOD (i.e., myocardial ischemia, left ventricular hypertrophy, systolic dysfunction, dias

271 cm) and 3- and 2-fold-higher prevalences of left ventricular hypertrophy than their normotensive cou

272 ause an accumulation of cardiac glycogen and left ventricular hypertrophy that mimics hypertrophic ca

273 the trigger, not the result, of pathological left ventricular hypertrophy through NF-kappaB-related p

274 sure overload accelerates the progression of left ventricular hypertrophy to heart failure in mice.

275 e-duration product, and Sokolow-Lyon voltage left ventricular hypertrophy treated as time-varying cov

276 betes mellitus, obesity, and the presence of left ventricular hypertrophy underwent maximal-effort up

277 a genetic disorder that is characterized by left ventricular hypertrophy unexplained by secondary ca

278 The OR for left ventricular hypertrophy was 4.8 in men (95% CI: 1.0

279 The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk as

280 Left ventricular hypertrophy was more prevalent in the O

281 Extreme left ventricular hypertrophy was most frequently associa

282 Left ventricular hypertrophy was observed in LKB1-KO mic

283 Left ventricular hypertrophy was particularly marked (ma

284 val [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per sq

285 Left ventricular hypertrophy was present in 144 athletes

286 At month 24, left ventricular hypertrophy was present in 41.7% versus

287 However, left ventricular hypertrophy was prevented by simvastati

288 Extreme left ventricular hypertrophy was the most common risk fa

289 Left ventricular hypertrophy was the most prevalent (29.

290 To assess the relationship between BP and left ventricular hypertrophy, we prospectively analyzed

291 ntricular ejection fraction, and presence of left ventricular hypertrophy were associated with greate

292 acement for aortic stenosis with evidence of left ventricular hypertrophy were randomly assigned to G

293 Hypertension and left ventricular hypertrophy were the risk factors most

294 mily A and family B men >30 years of age had left ventricular hypertrophy, which was mainly asymmetri

295 ertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in s

296 ECG left ventricular hypertrophy with strain is associated w

297 All patients showed asymmetrical left ventricular hypertrophy, with maximal left ventricu

298 ic response in an aortic-banded rat model of left ventricular hypertrophy, with reduced left ventricu

299 hout left ventricular hypertrophy (n=51) and left ventricular hypertrophy without ECG strain (n=30),

300 Extreme left ventricular hypertrophy (z-score: >6) and an abnorm